Dosimetry-Guided 90Y-DOTA-tyr3-Octreotide (90Y-DOTATOC) Peptide Receptor Radiotherapy (PRRT) in Children & Adults With Neuroendocrine and Other Somatostatin Receptor Expressing Tumors Determined by 68Ga-DOTA-tyr3-Octreotide (68Ga-DOTATOC) PET
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2018
At a glance
- Drugs Gallium 68-DOTATOC (Primary)
- Indications Medulloblastoma; Meningioma; Neuroblastoma; Neuroendocrine tumours
- Focus Therapeutic Use
- 14 Feb 2018 Planned End Date changed from 1 Jun 2018 to 25 Oct 2020.
- 14 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 25 Oct 2019.
- 27 Apr 2017 Status changed from recruiting to active, no longer recruiting.